Compare AAOI & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAOI | VCEL |
|---|---|---|
| Founded | 1997 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2013 | 1997 |
| Metric | AAOI | VCEL |
|---|---|---|
| Price | $34.84 | $37.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $33.60 | ★ $57.50 |
| AVG Volume (30 Days) | ★ 4.2M | 530.0K |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $421,712,000.00 | $258,716,999.00 |
| Revenue This Year | $85.89 | $17.86 |
| Revenue Next Year | $77.06 | $18.55 |
| P/E Ratio | ★ N/A | $152.87 |
| Revenue Growth | ★ 101.25 | 14.05 |
| 52 Week Low | $9.71 | $29.24 |
| 52 Week High | $41.96 | $63.00 |
| Indicator | AAOI | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 50.19 |
| Support Level | $35.37 | $35.85 |
| Resistance Level | $41.39 | $39.48 |
| Average True Range (ATR) | 3.23 | 1.89 |
| MACD | -0.33 | 0.00 |
| Stochastic Oscillator | 31.84 | 32.73 |
Applied Optoelectronics Inc is a provider of fiber-optic networking products, for four networking end-markets; internet data center, CATV, telecom, and FTTH. The Company designs and manufactures a wide range of optical communications products at varying levels of integration, from components, subassemblies, and modules to complete turn-key equipment. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The Company has manufacturing and research and development facilities located in the U.S., Taiwan, and China.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.